Key Points
- Samuel Kintz, CEO of Enliven Therapeutics, sold 12,500 shares on Nov. 17 at an average price of $21.82 for $272,750, reducing his stake by 1.38% to 890,392 shares; he has sold a total of 37,500 shares since mid‑September.
- Enliven shares trade around $22.58 (12‑month range $13.30–$26.48) with a market cap of ~$1.34B; the company reported Q3 EPS of -$0.32 (above estimates), analysts rate the stock a "Moderate Buy" with an average target of $41.20, and institutions own about 95% of the float.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $21.82, for a total transaction of $272,750.00. Following the transaction, the chief executive officer directly owned 890,392 shares in the company, valued at approximately $19,428,353.44. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.
Samuel Kintz also recently made the following trade(s):
- On Friday, October 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.33, for a total transaction of $266,625.00.
- On Friday, September 26th, Samuel Kintz sold 3,700 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.06, for a total transaction of $74,222.00.
- On Tuesday, September 23rd, Samuel Kintz sold 2,800 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.03, for a total transaction of $56,084.00.
- On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.25, for a total value of $20,250.00.
- On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $19.09, for a total value of $95,450.00.
Enliven Therapeutics Trading Down 0.1%
Shares of Enliven Therapeutics stock opened at $22.58 on Thursday. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $26.48. The firm has a market capitalization of $1.34 billion, a P/E ratio of -12.22 and a beta of 0.80. The business has a fifty day simple moving average of $20.38 and a two-hundred day simple moving average of $20.13.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. Analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Institutional Trading of Enliven Therapeutics
Large investors have recently made changes to their positions in the stock. Commodore Capital LP lifted its position in Enliven Therapeutics by 0.4% during the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company's stock valued at $94,138,000 after purchasing an additional 17,809 shares during the period. Polar Capital Holdings Plc grew its holdings in shares of Enliven Therapeutics by 1.5% in the third quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company's stock worth $63,355,000 after acquiring an additional 44,713 shares during the period. Vanguard Group Inc. increased its position in Enliven Therapeutics by 5.9% during the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company's stock valued at $52,260,000 after acquiring an additional 142,378 shares during the last quarter. Vestal Point Capital LP boosted its position in Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company's stock worth $23,745,000 after purchasing an additional 910,000 shares during the last quarter. Finally, Duquesne Family Office LLC increased its position in shares of Enliven Therapeutics by 104.6% during the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company's stock valued at $19,393,000 after purchasing an additional 484,405 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of analysts have recently commented on ELVN shares. Wall Street Zen raised Enliven Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Enliven Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $41.20.
Check Out Our Latest Research Report on Enliven Therapeutics
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
